Navigation Links
Summary Judgment Granted for SEROQUEL(R) Patent Litigation
Date:7/1/2008

uld accompany drug therapy.

The most commonly observed adverse reactions associated with the use of SEROQUEL versus placebo in clinical trials for schizophrenia and bipolar disorder were dry mouth (9%-44% vs 3%-13%), sedation (30% vs 8%), somnolence (18%-34% vs 7%-9%), dizziness (9%-18% vs 5%-7%), constipation (8%-10% vs 3%- 5%), asthenia (5%-10% vs 3%-4%), abdominal pain (4%-7% vs 1%-3%), postural hypotension (4%-7% vs 1%-2%), pharyngitis (4%-6% vs 3%), weight gain (5%-6% vs 1%-3%), lethargy (5% vs 2%), nasal congestion (5% vs 3%), SGPT increased (5% vs 1%), and dyspepsia (5%-7% vs 1%-4%).

In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% of patients receiving quetiapine (mean exposure 213 days) vs 4.6% in patients receiving placebo (mean exposure 152 days).

Please see Prescribing Information, including Boxed Warnings for SEROQUEL.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information visit http://www.astrazeneca-us.com.

The statements contain herein include forward-looking statements. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncert
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
2. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
3. Delay in Start of VNUS Patent Litigation and Court Ruling on Summary Judgment Motion
4. Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation
5. Par Pharmaceutical Provides Summary of Analyst/Investor Day
6. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
7. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
8. Exercising judgment: The psychology of fitness
9. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
10. St. Davids HealthCare Granted the States Top Honor for Quality and Performance Excellence
11. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... August 01, 2015 , ... The Honor Society ... Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, ... participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma ... store can be accessed by visiting http://www.curemeso.org/store . , “Our new store ... best part: whenever a product is purchased, the Meso Foundation receives a $5.00 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, ... has re-branded their social media profiles to better connect with the public. The ... communicate, find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... of surgeons and cosmetic experts gathered to see if they could reach a consensus ... procedures, including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on ...
(Date:7/31/2015)... ... 2015 , ... The 2015 New York Regional Conference on ... professionals, and researchers, covering a variety of topics related to mesothelioma and presented ... the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer Center. , The ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
... India's Knowledge Commission will soon come up with recommendations ... level to make it more competitive//, and to accommodate ... ,"We will come up with recommendations on the undergraduate ... he said, adding that a group has also been ...
... Research Institute at the University of Massachusetts listed about ... pollution//. This list is officially called the Toxic 100. ... of air pollution. This is based on air releases ... United States. , The various factors that ...
... to cancer is expected to be unsuccessful. Statisticians with the ... invested in the hunt for common inherited genetic variants that ... that there are a number of problems when doing such ... is that common genes are unlikely to exist nor ...
... enter the Guinness Book of World Records, but her achievement ... of 11 definitely makes her a wonder-kid. ,Born ... a medical practitioner, passed her Class 12 exam in the ... in the Basbadanpura area of this Rajasthan capital. ...
... coffee, coffee drinkers finally have something to cheer about. A ... three cups of coffee are protected from heart disease to ... Women's Health Study and has found that up to 60 ... free radicals in our bodies may come from coffee. ...
... be presented at the 29th Annual Scientific Sessions of ... that following// a methodical desensitization protocol might help patients ... to prevent the formation of new blockages in coronary ... to patients and physicians, and can lead to discontinuation ...
Cached Medicine News:Health News:Jaipur Girl’s Rare Feat: The Youngest To Pass Class 12 At The Age Of 1 2Health News:Clopidogrel Allergy Can Be Tackled By Methodical Desensitization 2
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... Calif., July 30, 2015  Amgen (NASDAQ: ... second quarter of 2015. Key results include: ... second quarter of 2014 to $5,370 million, with ... Enbrel ® (etanercept), Prolia ® (denosumab), ... and XGEVA ® (denosumab). Unfavorable changes in ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... Dong-A PharmTech Co. Ltd., announced that its ... III trials for udenafil, a new long acting drug ... double-blind, placebo-controlled trial is designed to evaluate the safety ... of phosphodiesterase versus placebo. The trials will be ...
... Nov. 4 CVS Caremark (NYSE: CVS ) ... position of SVP, Marketing for its pharmacy benefit management ... marketing from Jack Bruner, who is transitioning to the ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development 2Company Appoints New SVP, Marketing for PBM Business 2
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... of acute low back pain, they want ... restores functional mobility by providing powerful compression ... sizes that correspond directly to men's or ... reduce inventory requirements while simplifying the fitting ...
... effective immobilization of the cervical and upper ... that makes it well tolerated by patients. ... going from a stand-alone cervical collar, to ... a four-post orthosis. For these reasons, the ...
... laborious custom fabrication was required to produce ... and modifications in response to patient complaints ... evolved from two years of development and ... This orthosis can be quickly adjusted to ...
Medicine Products: